Core Viewpoint - Helaina, a New York-based startup, has achieved large-scale production of human lactoferrin through precision fermentation technology, with a capacity to meet the demand for 10 million servings per batch [1][3]. Company Overview - Helaina was founded in 2019 and has raised a total of $83 million, including $45 million in Series B funding [4]. - The company targets markets in women's health, sports nutrition, and digestive health, supplying effera as an ingredient to functional food, beverage, and supplement brands [4]. Product and Technology - Human lactoferrin is a bioactive protein crucial for iron balance, immune function, gut health, and normal inflammatory responses [3]. - Helaina uses genetically engineered yeast strains to express this protein, which has been self-certified as GRAS (Generally Recognized As Safe) [3]. - The company emphasizes that human lactoferrin is a superior choice compared to bovine lactoferrin, as it does not trigger antibody responses in humans [3]. Market Potential - The company sees the opportunity to create a new category in the market, focusing on clinically validated high-value bioactive substances [7]. - Helaina's products are positioned to address common issues such as iron deficiency in women and inflammation in sports nutrition [4][5]. Research and Development - Helaina conducts both internal research and clinical trials with partners to validate the efficacy of its products [6]. - The company aims to explore the significant impacts of low-dose supplementation of human lactoferrin and its potential benefits in muscle recovery when combined with creatine [6]. Strategic Partnerships - Helaina has established collaborations with various commercial partners, including Kroma Wellness and Mitsubishi International Food Ingredients, to expand its product offerings [1][4].

Core Viewpoint - The company, relying on an AI-driven synthetic biology technology platform, has developed several internationally competitive original technologies and established a rich product pipeline [1][2]. Group 1: Company Overview - Founded in 2015, the company has received over 400 million yuan in exclusive investment from Eli Lilly Asia Fund, making it one of the few synthetic biology enterprises with full-chain capabilities from R&D to production and commercialization [2]. - The company operates from its headquarters in Suzhou, with dual R&D centers in China and the U.S., and production bases in Hunan and Anhui, achieving an annual comprehensive production capacity exceeding 10,000 tons [3]. Group 2: Product and Market Development - The company has achieved stable supply and large-scale production of key raw materials, including the antibiotic raw material Florfenicol, pharmaceutical intermediates like NMN/NAD, and animal nutrition raw materials such as 25-hydroxyvitamin D3 [5]. - Its products are exported to over 20 countries globally, with a continuous increase in market share [1]. Group 3: Industry Events - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI-enabled biological manufacturing and featuring discussions on green chemicals, new materials, future food, and agriculture [8][9].

Core Viewpoint - The SynBioCon 2025 conference will focus on the integration of AI with biomanufacturing, green chemicals and new materials, future food, and future agriculture, aiming to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period [1]. Organizers and Support Units - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. and supported by various institutions including Peking University Ningbo Institute of Ocean Medicine and the China Society of Biotechnology [2]. Expert Guests - Notable experts include Zhang Xian'en, Dean of the School of Synthetic Biology at Shenzhen University, and other prominent figures from various universities and research institutes who will share insights on biomanufacturing innovations [4][5][6][7]. Conference Agenda - The event will feature a series of forums and discussions, including a high-level roundtable on biomanufacturing, thematic forums on green chemicals and new materials, AI in biomanufacturing, and future food and agriculture [36][37]. Key Topics of Discussion - Topics will cover the construction of efficient cell factories for aromatic compounds, biomanufacturing of polyamide materials, and advancements in enzyme engineering for low-carbon biomanufacturing [8][11][27]. Networking and Collaboration - The conference aims to facilitate technology transfer, product scaling, and talent acquisition within the biomanufacturing sector, promoting collaboration among industry leaders, researchers, and government entities [1]. Event Details - The conference will take place from August 20 to 22, 2025, in Ningbo, Zhejiang, featuring registration, networking opportunities, and a showcase of technological achievements in biomanufacturing [1][36].

Core Viewpoint - The company Jindawei expects a significant increase in net profit for the first half of 2025, driven by sales growth in Coenzyme Q10, Vitamin A, and domestic health products [1][3]. Group 1: Financial Performance - Jindawei anticipates a net profit attributable to shareholders of 221 million to 260 million yuan for the first half of 2025, representing a year-on-year growth of 70% to 100% [1]. - The expected non-net profit is projected to be between 220 million and 259 million yuan, also reflecting a year-on-year increase of 70% to 100% [1]. - The basic earnings per share are estimated to be between 0.36 yuan and 0.42 yuan [1]. Group 2: Business Overview - Jindawei primarily engages in the research, production, and sales of nutritional health foods and feed additives, with a high export ratio for raw materials [3]. - The company operates in both upstream raw material supply and downstream brand operation, making it a rare full-industry chain player in the health food sector [5]. Group 3: Product Development - In the raw material sector, Jindawei utilizes synthetic biology for large-scale production of products like Coenzyme Q10, NMN, and DHA, among others [4]. - The company holds the largest global market share in Coenzyme Q10, benefiting from cost and scale advantages [4]. - Jindawei is focused on reducing production costs for products like astaxanthin and DHA to enhance market competitiveness [4]. Group 4: Marketing Strategy - The company plans to leverage market insights and resource integration to develop product strategies and create market-leading products [6]. - Jindawei aims to enhance its operational capabilities and increase its market share in domestic health products by utilizing its advantages in raw material research and production [5].

Core Viewpoint - The SynBioCon 2025 conference will focus on the integration of AI with biomanufacturing, green chemicals and new materials, future food, and future agriculture, aiming to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period [1]. Group 1: Conference Overview - The conference will take place from August 20 to 22, 2025, in Ningbo, Zhejiang [1]. - It aims to promote the transfer and transformation of scientific and technological achievements, product scaling, and talent acquisition in the biomanufacturing sector [1]. Group 2: Organizers and Support Units - Organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by several academic and research institutions [2]. - Supported by various associations and alliances, including the Chinese Society of Biotechnology and the Zhejiang Synthetic Biology Industry Technology Alliance [2]. Group 3: Expert Guests - Notable experts include Zhang Xian'en, Dean of the School of Synthetic Biology at Shenzhen University of Technology, and other prominent figures in the field of biomanufacturing [4][5][6]. - The conference will feature presentations from experts on topics such as the construction of efficient cell factories and the biomanufacturing of key industrial monomers [8][11][30]. Group 4: Conference Agenda - The agenda includes a series of forums and discussions on topics like green chemicals, AI in biomanufacturing, and future food and agriculture [36][37]. - Activities will include a high-level roundtable on biomanufacturing and a youth forum to showcase innovative achievements in the industry [36].

Core Insights - The article highlights the ongoing development and innovation in the synthetic biology and biomanufacturing sectors in China, with a focus on Guangdong province, particularly Guangzhou and Shenzhen, which are leading in policy support and innovation outcomes [2][3]. Summary by Sections Industry Overview - Guangdong province's biomanufacturing industry is valued at approximately 1.3 trillion yuan, ranking third nationally, with plans to elevate the industry to a trillion-yuan scale through the "Action Plan for Accelerating the Construction of Biomanufacturing Industry Innovation High Ground" [2]. - Shenzhen has positioned synthetic biology as one of its "20+8" future industries, establishing a comprehensive support system for biomanufacturing, including a major synthetic biology infrastructure and a national innovation center [2]. Company Rankings - SynBioCon has released the "Top 500 Representative Enterprises in Biomanufacturing (Guangdong Edition)," featuring 76 companies recognized for their competitiveness based on team, core products, and diverse possibilities [3]. Upcoming Events - The "China Biomanufacturing Industry Map (2025)" will be published in August 2025, with a focus on 500 representative enterprises in biomanufacturing [1]. - The Fourth Synthetic Biology and Green Biomanufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals, new materials, future food, and agriculture [12][14].

Core Viewpoint - The article highlights the journey and contributions of Qi Qingsheng in the field of microbiology, emphasizing his role in synthetic biology, biomanufacturing, and resource recycling, as well as his commitment to education and nurturing future talents in the discipline [1][9][19]. Group 1: Academic Journey - Qi Qingsheng's interest in microbiology was sparked by a chance encounter with microbiologist Wang Zunong, leading him to excel in the field at Shandong University [3][4]. - He faced challenges during his undergraduate studies due to the extensive memorization required in microbiology, which later helped him guide students in overcoming academic hurdles [5]. - After completing his master's degree in 1992, he joined the team to establish the National Key Laboratory of Microbial Technology, overcoming initial hardships to lay a solid foundation for future research [6][9]. Group 2: Research Contributions - Upon returning from Germany with a PhD in molecular microbiology, Qi recognized the potential of synthetic biology in China and began promoting its application domestically in 2008 [9][11]. - He led significant projects focusing on the biodegradation of waste plastics, securing 15 million in funding for international collaboration in 2018, demonstrating the integration of synthetic biology with circular economy principles [11][19]. Group 3: Educational Impact - Qi has mentored over 160 students, emphasizing the importance of mutual effort between mentors and students in achieving academic success [13][14]. - He encourages students to engage in research projects to enhance their practical skills and understanding of theoretical concepts, advocating for a balance between hard work and awareness of scientific trends [15][19]. Group 4: Future of Microbiology - Qi expresses confidence in the broad applications of microbiology across various sectors, including food fermentation, environmental protection, and biomanufacturing, urging young scholars to explore unknown fields [18][19]. - He stresses the need for microbiology to align with national strategic demands and to bridge the gap between fundamental research and industrial application [19][21].

Core Viewpoint - Tianjin Hesheng Biotechnology Co., Ltd. has completed a multi-million Pre-A round financing, which will accelerate its technological innovation in the synthetic biology field and lead new trends in health and nutrition solutions [1][2]. Group 1: Company Overview - Established in August 2023, Hesheng Biotechnology is a key technology transfer enterprise of Nankai University, gathering a leading research team in synthetic biology with nearly 30 years of experience [2]. - The company has developed a "DBTL" (Design-Build-Test-Learn) technical platform, utilizing proprietary gene element databases and self-developed AI algorithms to create high-productivity microbial strains [2]. - Hesheng Biotechnology has a comprehensive technical coverage from product research and development to downstream applications, focusing on probiotics, functional foods, and medical foods [2]. Group 2: Key Product Focus - Human Milk Oligosaccharides (HMOs) - The core technology for Hesheng Biotechnology's HMO products originates from the National Key Basic Research Program (973 Program), with the team first synthesizing HMOs in 2016 and obtaining invention patents for industrial strains [3]. - The company has developed several industrial strain construction technologies for HMOs, including 2'-FL, 3-FL, and others, with a product purity of 98.98%, significantly exceeding domestic and international quality standards [3][4]. Group 3: Research and Application - Hesheng Biotechnology is committed to independent innovation and has initiated research on the functional applications of HMOs, including their role in immune balance and disease intervention [4].

Core Viewpoint - The article discusses the current state and future potential of bioplastics, highlighting the advancements in microbial production of plastic monomers and the challenges faced in achieving industrial-scale production [1][2]. Group 1: Bioplastics Market Overview - The representative bioplastics in the market include PBAT, PLA, PBS, PA, PTT, and PET, which together account for approximately 65% of the total bioplastics market share [1]. - It is projected that by 2025, the annual market share of bioplastics will increase to 18% of the total plastics market [1]. Group 2: Challenges in Microbial Production - The economic feasibility of certain monomers remains low, posing challenges for industrial-scale microbial production [2]. - Key challenges include low raw material utilization efficiency, poor monomer synthesis efficiency due to complex microbial metabolic networks, and weak environmental tolerance of microorganisms during fermentation [2]. Group 3: Technological Developments - A research team led by Professor Liu Liming and Associate Researcher Gao Cong from Jiangnan University has developed key technologies for the high-yield production of plastic monomers such as 1,3-propanediol, succinic acid, and pentamethylenediamine [3]. Group 4: Upcoming Events - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing, as well as advancements in green chemistry and new materials [10][11].

Project Overview - The project is named "Annual Production of 855 Tons of Green Active Raw Materials" and is initiated by Shandong Yunluo Biotechnology Co., Ltd. [2] - The total estimated investment for the project is 100 million yuan, with 7.5% allocated for environmental protection, amounting to 7.5 million yuan [2]. - The construction period is planned for one year, and the project will utilize existing factory buildings while acquiring new production equipment [2]. Production Capacity - Upon reaching full production capacity, the project is expected to produce 1 ton of probiotics, 5 tons of ergothioneine, 126 tons of ectoine, 250 tons of hydroxypropyl tetrahydropyran triol (Bosein), and 473 tons of gluconic acid annually [2][3]. - The products will be sold externally and adhere to the company's quality standards [3]. Company Background - Shandong Yunluo Biotechnology Co., Ltd. is a wholly-owned subsidiary of Shanghai Yunluo Biotechnology Co., Ltd. [3]. - The company focuses on synthetic biology, specializing in enzyme gene mining, directed enzyme modification, cell factory construction, biological fermentation, and enzyme catalysis [3]. Industry Event - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang [5]. - The conference will focus on the integration of AI and biological manufacturing, as well as the industrialization progress and opportunities in green chemistry, new materials, future food, and agriculture [5]. - Various stakeholders, including international enterprises, industry experts, and government representatives, will participate to explore trends in biological manufacturing and innovation [5].